NCT00898677

Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)

A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of Single Oral Doses of MK0462 5 mg, MK0462 10 mg, and Sumatriptan 100 mg for Acute Treatment of Migraine

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,268 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A study to compare rizatriptan 10 mg verse sumatriptan 100 mg in the treatment of migraine attacks and duration of relief provided. This study will also provide additional efficacy data on rizatriptan 5 mg and 10 mg for the treatment of migraine.

Conditions

• Migraine Headache

Interventions

Type	Name	Description
DRUG	rizatriptan benzoate	single dose administration of 5mg rizatriptan (by Mouth) p.o.
DRUG	rizatriptan benzoate	single dose administration of 10 mg rizatriptan p.o.
DRUG	Comparator: sumatriptan	single dose administration of sumatriptan 100 p.o.
DRUG	Comparator: Placebo	placebo to rizatriptan

Timeline

• Start date: 1995-09-01
• Primary completion: 1996-05-01
• Completion: 1996-09-01
• First posted: 2009-05-12
• Last updated: 2022-02-03
• Results posted: 2009-07-14